Screening of biomarkers for lung cancer with gene expression profiling data

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 23, 2013, Pages 3221-3228

  Wu, Q P ^a   Min, Jiaxin ^a   Jiang, L ^a   Li, J M ^a   Yao, K ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; CCNA2; CHEK1; Functional enrichment analysis; Interaction network; Lung cancer

Indexed keywords

ARTICLE; CANCER SCREENING; CANCER TISSUE; CELL CYCLE; DNA REPLICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE ONTOLOGY; HUMAN; IMMUNE SYSTEM; LUNG CANCER; MICROARRAY ANALYSIS; ONCOGENE; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GENE;

CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEIN INTERACTION MAPS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891797879     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. ROSSO T, MALVEZZI M, BERTUCCIO P, NEGRI E, LA VECCHIA C, DECARLI A. Cancer mortality in Italy, 2008, and predictions for 2012. Tumori 2012; 98: 559-567.
2. SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
3. SAMET JM, WIGGINS CL, HUMBLE CG, PATHAK DR. Cigarette smoking and lung cancer in New Mexico. Am Rev Respir Dis 1988; 137: 1110-1113.
4. BIESALSKI HK, BUENO DE MESQUITA B, CHESSON A, CHYTIL F, GRIMBLE R, HERMUS RJ, KOHRLE J, LOTAN R, NORPOTH K, PASTORINO U, THURNHAM D. European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. CA Cancer J Clin 1998; 48: 167-176; discussion 164-166.
5. POPE CA, 3RD, BURNETT RT, THUN MJ, CALLE EE, KREWSKI D, ITO K, THURSTON GD. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 2002; 287: 1132-1141.
6. VALAVANIDIS A, FIOTAKIS K, VLACHOGIANNI T. Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2008; 26: 339-362.
7. FONG KM, SEKIDO Y, GAZDAR AF, MINNA JD. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax 2003; 58: 892-900.
8. SALGIA R, SKARIN AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998; 16: 1207-1217.
9. HERBST RS, HEYMACH JV, LIPPMAN SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
10. SORIANO C, MUKARO V, HODGE G, AHERN J, HOLMES M, JERSMANN H, MOFFAT D, Meredith D, Jurisevic C, Reynolds PN, Hodge S. Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion? Lung Cancer 2012; 77: 38-45.
11. CHEN C, QU QX, SHEN Y, MU CY, ZHU YB, ZHANG XG, HUANG JA. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett 2012; 317: 99-105.
12. YANG L, LIN M, RUAN WJ, DONG LL, CHEN EG, WU XH, YING KJ. Nkx2-1: a novel tumor biomarker of lung cancer. J Zhejiang Univ Sci B 2012; 13: 855-866.
13. TANAKA S, HATTORI N, ISHIKAWA N, HORIMASU Y, DEGUCHI N, TAKANO A, TOMODA Y, YOSHIOKA K, FUJITAKA K, ARIHIRO K, OKADA M, YOKOYAMA A, KOHNO N. Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer. Pathobiology 2012; 79: 24-33.
14. TAN F, JIANG Y, SUN N, CHEN Z, LV Y, SHAO K, LI N, QIU B, GAO Y, LI B, TAN X, ZHOU F, WANG Z, DING D, WANG J, SUN J, HANG J, SHI S, FENG X, HE F, HE J. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteomics 2012; 11: M111 008821.
15. WU X, ZANG W, CUI S, WANG M. Bioinformatics analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. Eur Rev Med Pharmacol Sci 2012; 16: 1582-1587.
16. YUXIA M, ZHENNAN T, WEI Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 2012; 138: 2045-2050.
17. GUO W, ZHANG Y, GE D, ZHANG Y, LU C, WANG Q, FAN H. Bioinformatics analyses combined microarray identify the desregulated MicroRNAs in lung cancer. Eur Rev Med Pharmacol Sci 2013; 17: 1509-1516.
18. HOU J, AERTS J, DEN HAMER B, VAN IJCKEN W, DEN BAKKER M, RIEGMAN P, VAN DER LEEST C, VAN DER SPEK P, FOEKENS JA, HOOGSTEDEN HC, GROSVELD F, PHILIPSEN S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One; 5: e10312.
19. IRIZARRY RA, HOBBS B, COLLIN F, BEAZER-BARCLAY YD, ANTONELLIS KJ, SCHERF U, SPEED TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
20. BOLSTAD BM, IRIZARRY RA, ASTRAND M, SPEED TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
21. HUANG DA W, SHERMAN BT, LEMPICKI RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
22. PERI S, NAVARRO JD, AMANCHY R, KRISTIANSEN TZ, JONNALAGADDA CK, SURENDRANATH V, NIRANJAN V, MUTHUSAMY B, GANDHI TK, GRONBORG M, IBARROLA N, DESHPANDE N, SHANKER K, SHIVASHANKAR HN, RASHMI BP, RAMYA MA, ZHAO Z, CHANDRIKA KN, PADMA N, HARSHA HC, YATISH AJ, KAVITHA MP, MENEZES M, CHOUDHURY DR, SURESH S, GHOSH N, SARAVANA R, CHANDRAN S, KRISHNA S, JOY M, ANAND SK, MADAVAN V, JOSEPH A, WONG GW, SCHIEMANN WP, CONSTANTINESCU SN, HUANG L, KHOSRAVI-FAR R, STEEN H, TEWARI M, GHAFFARI S, BLOBE GC, DANG CV, GARCIA JG, PEVSNER J, JENSEN ON, ROEPSTORFF P, DESHPANDE KS, CHINNAIYAN AM, HAMOSH A, CHAKRAVARTI A, PANDEY A. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003; 13: 2363-2371.
23. GONG X, WU R, ZHANG Y, ZHAO W, CHENG L, GU Y, ZHANG L, WANG J, ZHU J, GUO Z. Extracting consistent knowledge from highly inconsistent cancer gene data sources. BMC Bioinformatics 2010; 11: 76.
24. JONSSON PF, BATES PA. Global topological features of cancer proteins in the human interactome. Bioinformatics 2006; 22: 2291-2297.
25. ARSIC N, BENDRIS N, PETER M, BEGON-PESCIA C, REBOUISSOU C, GADEA G, BOUQUIER N, BIBEAU F, LEMMERS B, BLANCHARD JM. A novel function for Cyclin A2: control of cell invasion via RhoA signaling. J Cell Biol; 196: 147-162.
26. WANG L, XIONG Y, SUN Y, FANG Z, LI L, JI H, SHI T. HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res 2010; 38: D665-D669.
27. KO E, KIM Y, CHO EY, HAN J, SHIM YM, PARK J, KIM DH. Synergistic Effect of Bcl-2 and Cyclin A2 on Adverse Recurrence-Free Survival in Stage I Non-small Cell Lung Cancer. Ann Surg Oncol 2013; 20: 1005-1012.
28. LI M, WANG X, TAN Z, DONG P, GU J, LU J, WU X, ZHANG L, DING Q, WU W. Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-rage axis. Int J Immunopathol Pharmacol 2011; 25: 955-965.
29. LI Q, ZHU GD. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem 2002; 2: 939-971.
30. COLLINS I, GARRETT MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005; 5: 366-373.
31. XIAO Z, XUE J, SOWIN TJ, ZHANG H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006; 5: 1935-1943.
32. TSE AN, CARVAJAL R, SCHWARTZ GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13: 1955-1960.
33. HERMAN-ANTOSIEWICZ A, SINGH SV. Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells. J Biol Chem 2005; 280: 28519-28528.
34. YANG H, YOON SJ, JIN J, CHOI SH, SEOL HJ, LEE JI, NAM DH, YOO HY. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun 2011; 406: 53-58.
35. WEISS GJ, DONEHOWER RC, IYENGAR T, RAMANATHAN RK, LEWANDOWSKI K, WESTIN E, HURT K, HYNES SM, ANTHONY SP, MCKANE S. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs 2013; 31: 136-144.
36. WANG J, XU B, YUAN P, ZHANG P, LI Q, MA F, FAN Y. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat 2012; 135: 531-537.
37. CHEN W, QIU J, SHEN YM. Topoisomerase IIalpha, rather than IIbeta, is a promising target in development of anti-cancer drugs. Drug Discov Ther 2012; 6: 230-237.
38. LIN TY, HUANG CP, AU LC, CHANG YW, HU CY, LIN SB. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIalpha, enhances DNA breakage, and induces apoptosis in cancer cells. Chem Res Toxicol 2012; 25: 2340-2351.
39. RIJAVEC M, SILAR M, TRILLER N, KERN I, CEGOVNIK U, KOSNIK M, KOROSEC P. Expressions of topoisomerase IIalpha and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients. Pathol Oncol Res 2011; 17: 691-696.
40. KUBO A, YOSHIKAWA A, HIRASHIMA T, MASUDA N, TAKADA M, TAKAHARA J, FUKUOKA M, NAKAGAWA K. Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide. Cancer Res 1996; 56: 1232-1236.
41. FAN L, WANG H, XIA X, RAO Y, MA X, MA D, WU P, CHEN G. Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression. Oncol Lett 2012; 4: 1225-1233.
42. ZVRKO E, MIKIC A, JANCIC S. Relationship of E-cadherin with cervical lymph node metastasis in laryngeal cancer. Coll Antropol 2012; 36(Suppl 2): 119-124.
43. LU L, ZHOU D, JIANG X, SONG K, LI K, DING W. Loss of E-cadherin in multidrug resistant breast cancer cell line MCF-7/Adr: possible implication in the enhanced invasive ability. Eur Rev Med Pharmacol Sci 2012; 16: 1271-1279.
44. YUAN YL, WANG YM, LIU H, QIN GF, TANG AG, DUAN Y. Aberrant expression of E-cadherin in lung tissues of patients with probable lung cancer. Asian Pac J Cancer Prev 2012; 13: 5149-5153.
45. SHIWU WU , LAN Y, WENQING S, LEI Z, YISHENG T. Expression and clinical significance of CD82/KAI1 and E-cadherin in non-small cell lung cancer. Arch Iran Med 2012; 15: 707-712.
46. XING X, TANG YB, YUAN G, WANG Y, WANG J, YANG Y, CHEN M. The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer 2012; 132: 2589-2596.
47. FRY SA, SINCLAIR J, TIMMS JF, LEATHEM AJ, DWEK MV. A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer. Cancer Lett 2013; 328: 335-344.
48. VAN HORSSEN R, HOLLESTELLE A, RENS JA, EGGERMONT AM, SCHUTTE M, TEN HAGEN TL. E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells. Breast Cancer Res Treat 2012; 136: 365-377.
49. LIN Z, SHEN X, LU F, RUAN Z, HUANG H, ZHEN J. Reveals new lung adenocarcinoma cancer genes based on gene expression. Eur Rev Med Pharmacol Sci 2012; 16: 1249-1256.
50. LI B, LU Q, SONG Z, YANG L, JIN H, LI Z, ZHAO T, BAI Y, ZHU J, CHEN H. Functional analysis of DNA methylation in lung cancer. Eur Rev Med Pharmacol Sci 2013; 17: 1191-1197.